<?xml version='1.0' encoding='utf-8'?>
<document id="31299074"><sentence text="Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART."><entity charOffset="30-42" id="DDI-PubMed.31299074.s1.e0" text="etonogestrel" /><entity charOffset="79-88" id="DDI-PubMed.31299074.s1.e1" text="efavirenz" /><entity charOffset="92-102" id="DDI-PubMed.31299074.s1.e2" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.31299074.s1.e0" e2="DDI-PubMed.31299074.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s1.e0" e2="DDI-PubMed.31299074.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s1.e0" e2="DDI-PubMed.31299074.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s1.e1" e2="DDI-PubMed.31299074.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s1.e1" e2="DDI-PubMed.31299074.s1.e2" /></sentence><sentence text="We previously demonstrated that etonogestrel concentrations were 82% lower in women using etonogestrel contraceptive implants plus efavirenz-based ART compared with women not receiving ART"><entity charOffset="32-44" id="DDI-PubMed.31299074.s2.e0" text="etonogestrel" /><entity charOffset="90-102" id="DDI-PubMed.31299074.s2.e1" text="etonogestrel" /><entity charOffset="131-140" id="DDI-PubMed.31299074.s2.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.31299074.s2.e0" e2="DDI-PubMed.31299074.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s2.e0" e2="DDI-PubMed.31299074.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s2.e0" e2="DDI-PubMed.31299074.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s2.e1" e2="DDI-PubMed.31299074.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s2.e1" e2="DDI-PubMed.31299074.s2.e2" /></sentence><sentence text="" /><sentence text="To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes known to be involved in efavirenz, nevirapine or etonogestrel metabolism in the same group of women"><entity charOffset="145-154" id="DDI-PubMed.31299074.s4.e0" text="efavirenz" /><entity charOffset="156-166" id="DDI-PubMed.31299074.s4.e1" text="nevirapine" /><entity charOffset="170-182" id="DDI-PubMed.31299074.s4.e2" text="etonogestrel" /><pair ddi="false" e1="DDI-PubMed.31299074.s4.e0" e2="DDI-PubMed.31299074.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s4.e0" e2="DDI-PubMed.31299074.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s4.e0" e2="DDI-PubMed.31299074.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s4.e1" e2="DDI-PubMed.31299074.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s4.e1" e2="DDI-PubMed.31299074.s4.e2" /></sentence><sentence text="" /><sentence text="Here, we present a secondary analysis evaluating SNPs involved in efavirenz, nevirapine and etonogestrel metabolism and associated etonogestrel pharmacokinetics among 57 women, 19 not receiving ART (control group), 19 receiving efavirenz- (600 mg daily) based ART and 19 receiving nevirapine- (200 mg twice daily) based ART"><entity charOffset="66-75" id="DDI-PubMed.31299074.s6.e0" text="efavirenz" /><entity charOffset="77-87" id="DDI-PubMed.31299074.s6.e1" text="nevirapine" /><entity charOffset="92-104" id="DDI-PubMed.31299074.s6.e2" text="etonogestrel" /><entity charOffset="131-143" id="DDI-PubMed.31299074.s6.e3" text="etonogestrel" /><entity charOffset="228-238" id="DDI-PubMed.31299074.s6.e4" text="efavirenz-" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e0" e2="DDI-PubMed.31299074.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e0" e2="DDI-PubMed.31299074.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e0" e2="DDI-PubMed.31299074.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e0" e2="DDI-PubMed.31299074.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e0" e2="DDI-PubMed.31299074.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e1" e2="DDI-PubMed.31299074.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e1" e2="DDI-PubMed.31299074.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e1" e2="DDI-PubMed.31299074.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e1" e2="DDI-PubMed.31299074.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e2" e2="DDI-PubMed.31299074.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e2" e2="DDI-PubMed.31299074.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e2" e2="DDI-PubMed.31299074.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e3" e2="DDI-PubMed.31299074.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31299074.s6.e3" e2="DDI-PubMed.31299074.s6.e4" /></sentence><sentence text=" Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression" /><sentence text=" This study was registered at clinicaltrials" /><sentence text="gov (NCT02082652)" /><sentence text="" /><sentence text="Within the control group, CYP2B6 983 T&gt;C was associated with 27% higher etonogestrel Cmax and 28% higher AUC0-24weeks"><entity charOffset="72-84" id="DDI-PubMed.31299074.s11.e0" text="etonogestrel" /></sentence><sentence text=" In the efavirenz group CYP2B6 516 G&gt;T was associated with 43% lower etonogestrel Cmin and 34% lower AUC0-24weeks"><entity charOffset="8-17" id="DDI-PubMed.31299074.s12.e0" text="efavirenz" /><entity charOffset="69-81" id="DDI-PubMed.31299074.s12.e1" text="etonogestrel" /><pair ddi="false" e1="DDI-PubMed.31299074.s12.e0" e2="DDI-PubMed.31299074.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s12.e0" e2="DDI-PubMed.31299074.s12.e1" /></sentence><sentence text=" For participants receiving nevirapine, NR1I2 63396 C&gt;T was associated with 39% lower etonogestrel Cmin and 37% lower AUC0-24weeks"><entity charOffset="28-38" id="DDI-PubMed.31299074.s13.e0" text="nevirapine" /><entity charOffset="86-98" id="DDI-PubMed.31299074.s13.e1" text="etonogestrel" /><pair ddi="false" e1="DDI-PubMed.31299074.s13.e0" e2="DDI-PubMed.31299074.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s13.e0" e2="DDI-PubMed.31299074.s13.e1" /></sentence><sentence text="" /><sentence text="This study demonstrates the influence of pharmacogenetics on the extent of drug-drug interactions between etonogestrel and efavirenz- or nevirapine-based ART"><entity charOffset="106-118" id="DDI-PubMed.31299074.s15.e0" text="etonogestrel" /><entity charOffset="123-133" id="DDI-PubMed.31299074.s15.e1" text="efavirenz-" /><entity charOffset="137-147" id="DDI-PubMed.31299074.s15.e2" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.31299074.s15.e0" e2="DDI-PubMed.31299074.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s15.e0" e2="DDI-PubMed.31299074.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s15.e0" e2="DDI-PubMed.31299074.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31299074.s15.e1" e2="DDI-PubMed.31299074.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31299074.s15.e1" e2="DDI-PubMed.31299074.s15.e2" /></sentence><sentence text=" Efavirenz plus the etonogestrel contraceptive implant results in a detrimental drug-drug interaction irrespective of patient genetics, which is worsened in women possessing variant alleles for these CYP2B6 SNPs"><entity charOffset="1-10" id="DDI-PubMed.31299074.s16.e0" text="Efavirenz" /><entity charOffset="20-32" id="DDI-PubMed.31299074.s16.e1" text="etonogestrel" /><pair ddi="false" e1="DDI-PubMed.31299074.s16.e0" e2="DDI-PubMed.31299074.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31299074.s16.e0" e2="DDI-PubMed.31299074.s16.e1" /></sentence><sentence text="" /></document>